ArticleBritish journal of cancer2009
Overexpression of E2F-5 correlates with a pathological basal phenotype and a worse clinical outcome.
Article in British journal of cancer, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 57 citations in OpenAlex.
- Insight into mammary gland development and tumor progression in an E2F5 conditional knockout mouse model.Oncogene · 2024Article
- Role of non-coding RNAs and exosomal non-coding RNAs in retinoblastoma progression.Frontiers in cell and developmental biology · 2022Review
- CDK13 upregulation-induced formation of the positive feedback loop among circCDK13, miR-212-5p/miR-449a and E2F5 contributes to prostate carcinogenesis.Journal of experimental & clinical cancer research : CR · 2021Article
- Article
- The broken cycle: E2F dysfunction in cancer.Nature reviews. Cancer · 2019Review
- The Proliferative and Apoptotic Landscape of Basal-like Breast Cancer.International journal of molecular sciences · 2019Review
- E2F6 is essential for cell viability in breast cancer cells during replication stress.Turkish journal of biology = Turk biyoloji dergisi · 2019Article
- Combined Androgen receptor blockade overcomes the resistance of breast cancer cells to palbociclib.International journal of biological sciences · 2019Article
- Expression patterns of E2F transcription factors and their potential prognostic roles in breast cancer.Oncology letters · 2018Article
- MicroRNA-Directed Cancer Therapies: Implications in Melanoma Intervention.The Journal of pharmacology and experimental therapeutics · 2018Review
- Expressions and prognostic values of theCancer management and research · 2018Review
- Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence.Oncogene · 2017Article
- The transcription factor FOXN3 inhibits cell proliferation by downregulating E2F5 expression in hepatocellular carcinoma cells.Oncotarget · 2016Article
- Upregulation of E2F8 promotes cell proliferation and tumorigenicity in breast cancer by modulating G1/S phase transition.Oncotarget · 2016Article
- MicroRNA-154 inhibits growth and invasion of breast cancer cells through targeting E2F5.American journal of translational research · 2016Article
- The role of microRNAs and long non-coding RNAs in the pathology, diagnosis, and management of melanoma.Archives of biochemistry and biophysics · 2014Review
- xCT, component of cysteine/glutamate transporter, as an independent prognostic factor in human esophageal squamous cell carcinoma.Journal of gastroenterology · 2014Article
- 3'LIFE: a functional assay to detect miRNA targets in high-throughput.Nucleic acids research · 2014Article
- Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The purpose of the present study is to identify genes that contribute to cell proliferation or differentiation of breast cancers independent of signalling through the oestrogen receptor (ER) or human epidermal growth factor receptor 2 (HER2). An oligonucleotide microarray assayed 40 tumour samples from ER(+)/HER2(-), ER(+)/HER2(+), ER(-)/HER2(+), and ER(-)/HER2(-) breast cancer tissues. Quantitative reverse transcriptase PCR detected overexpression of a cell cycle-related transcription factor, E2F-5, in ER-negative breast cancers, and fluorescence in situ hybridisation detected gene amplification of E2F-5 in 5 out of 57 (8.8%) breast cancer samples. No point mutations were found in the DNA-binding or DNA-dimerisation domain of E2F-5. Immunohistochemically, E2F-5-positive cancers correlated with a higher Ki-67 labelling index (59.5%, P=0.001) and higher histological grades (P=0.049). E2F-5-positive cancers were found more frequently in ER(-)/progesterone receptor (PgR)(-)/HER2(-) cancer samples (51.9%, P=0.0049) and in breast cancer samples exhibiting a basal phenotype (56.0%, P=0.0012). Disease-free survival in node-negative patients with E2F-5-positive cancers was shorter than for patients with E2F-5-negative cancers. In conclusion, we identify, for the first time, a population of breast cancer cells that overexpress the cell cycle-related transcription factor, E2F-5. This E2F-5-positive breast cancer subtype was associated with an ER(-)/PgR(-)/HER2(-) status, a basal phenotype, and a worse clinical outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.